Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
Moodys
Medtronic
Mallinckrodt
Colorcon
Johnson and Johnson

Last Updated: November 12, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,605,300

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,605,300
Title: Oral pulsed dose drug delivery system
Abstract:A multiple pulsed dose drug delivery system for pharmaceutically active amphetamine salts, comprising an immediate-release component and an enteric delayed-release component wherein (1) the enteric release coating has a defined minimum thickness and/or (2) there is a protective layer between the pharmaceutically active amphetamine salt and the enteric release coating and/or (3) there is a protective layer over the enteric release coating. The product can be composed of either one or a number of beads in a dosage form, including either capsule, tablet, or sachet method for administering the beads.
Inventor(s): Burnside; Beth A. (Silver Spring, MD), Guo; Xiaodi (Derwood, MD), Fiske; Kimberly (Alexandria, VA), Couch; Richard A. (Bethesda, MD), Treacy; Donald J. (Arnold, MD), Chang; Rong-Kun (Hockessin, DE), McGuinness; Charlotte M. (Bethesda, MD), Rudnic; Edward M. (North Potomac, MD)
Assignee: Shire Laboratories, Inc. (Rockville, MD)
Application Number:09/807,462
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,605,300
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Dosage form; Delivery;

Drugs Protected by US Patent 6,605,300

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Shire ADDERALL XR 10 amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate CAPSULE, EXTENDED RELEASE;ORAL 021303-001 Oct 11, 2001 AB RX Yes No   Start Trial   Start Trial   Start Trial
Shire ADDERALL XR 15 amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate CAPSULE, EXTENDED RELEASE;ORAL 021303-006 May 22, 2002 AB RX Yes No   Start Trial   Start Trial   Start Trial
Shire ADDERALL XR 20 amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate CAPSULE, EXTENDED RELEASE;ORAL 021303-002 Oct 11, 2001 AB RX Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,605,300

PCT Information
PCT FiledOctober 20, 1999PCT Application Number:PCT/US99/24554
PCT Publication Date:April 27, 2000PCT Publication Number: WO00/23055

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
Johnson and Johnson
Dow
AstraZeneca
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.